BridgeBio

Did you know that some people may be living with abnormal calcium levels that impact their quality of life without ever knowing it? Many people simply adapt to chronically low calcium. They live with brain fog, muscle fatigue, and tingling sensations, and assume it's just how they feel. Over time, this may lead to serious complications such as kidney disease, seizures, or brain calcifications. But some people living with low calcium levels may not realize their symptoms are connected to a genetic hypoparathyroidism condition called #ADH1. Recently, relatives of people diagnosed with ADH1 came together in Oklahoma City for a genetic testing event hosted by the patient advocacy group, HypoPARAthyroidism Association (HPA). It was similar to a family reunion with cousins, parents, and grandchildren all getting a genetic testing cheek swab at the same time. Watch this video to hear directly from families about why genetic testing matters and how awareness can help people take the next step toward understanding their health: https://bit.ly/4bM7AcB

We were grateful to attend #NORD’s Living Rare conference alongside GondolaBio, a company part of our ecosystem, last week and be part of conversations that fostered support, connection, and access to valuable local resources for patients and caregivers.

"No one's doing genetic disease research right now. I could call an academic after they publish and be the first company calling them.” - Neil Kumar, our Co-Founder & CEO, at the #STATBreakthrough Summit West That's not a complaint. That's an opening. While others follow pharma's acquisition wish list, we are racing to develop treatments for people with genetic diseases who have none. Three potential FDA approvals on the horizon. A pipeline built on contrarian bets, not conventional wisdom. This is what building an independent biotech company looks like.

New post-hoc exploratory data in the Journal of Cardiac Failure examines serum TTR, cardiovascular mortality & hospitalization, and treatment with a TTR stabilizer in patients with ATTR-CM. Serum #TTR may serve as a clinically informative biomarker for ATTR-CM cardiovascular risk assessment following stabilizer initiation. Learn more: https://bit.ly/4wrDi7i

We are excited to share that the ADH1 Commercial sales team is growing! Matthew Mitchell and Alyson Kempton are actively hiring talented Endocrine Account Managers in the West and Northeast regions. We're searching for individuals who are mission-driven, collaborative, and passionate about making a meaningful impact—bringing strong customer engagement skills, launch excellence, and a commitment to supporting individuals living with ADH1. If you're interested – or know someone who might be a great addition – check out our Careers page to learn more: https://bit.ly/3RNkFe8

🚀 A major step forward for the limb-girdle muscular dystrophy (LGMD) community is here! The Muscular Dystrophy Association and BridgeBio are partnering on a $100,000 investment to strengthen multidisciplinary care for people living with LGMD at leading MDA Care Centers at Stanford Health Care and the University of Minnesota. These innovative projects will help expand access to care, strengthen coordination across specialties, and support hybrid care models that meet patients where they are. 🩺✨ 🔗Read the full story: https://lnkd.in/g_jQhvy6 #MultidisciplinaryCare #LGMD #MuscularDystrophy #Neuromuscular #MDA

What an incredible evening at the annual University of the Pacific Biotech Mixer! 🧬 Events like this are a reminder of why community matters in biotech and pharma — the connections made between fellows, students, alumni, faculty, and industry professionals are what move our field forward. We're proud to be part of the Fellowship in Industry Program, which is making a real difference in building the next generation of healthcare leaders.

Our team recently traveled to Reston, VA for the National Tay-Sachs & Allied Diseases Association Annual Family Conference. NTSAD is a valued patient advocacy partner, and this conference is a powerful reminder of why our work matters. We had the opportunity to present an update on our #Canavan program, but the highlight, as always, was the time spent with families. The conversations, the connections, and the trust they place in us fuel everything we do. Thank you to NTSAD for bringing this community together. We are honored to be part of it.

What a fantastic #PES2026! It was an incredible week connecting with the pediatric endocrinology community across our three booths — BridgeBio Endocrinology, BridgeBio Skeletal Dysplasias, and Suspect and Detect ADH1. We were proud to have skeletal dysplasias posters presented during the meeting and grateful for the meaningful time spent with patient advocacy groups, including the HypoPARAthyroidism Association. Conversations like these remind us why this work matters. We're already looking forward to PES 2027!

Building an independent biotech company is rare. And for good reason – it doesn’t come easy.   Our CEO Neil Kumar will take the stage at the #STATBreakthrough Summit West in San Francisco alongside Will Lewis, CEO of Insmed Incorporated, for a conversation with STAT senior biotech columnist Adam Feuerstein on what it takes to build and scale an independent commercial biotech.    Most companies in this industry are built with an acquisition in mind. Neil and Will have chosen a different path: staying independent so that nothing slows down the work of getting medicines to patients who need them.   We exist to turn beautiful science into treatments for people living with genetic diseases.   Join us on May 19 in San Francisco.